BioDelivery Sciences picks up US rights to opioid-induced constipation drug Symproic

11 April 2019

Shionogi (TYO: 4507) says it has out-licensed full US commercialization rights for its approved medication, Symproic (naldemedine).

The Japanese firm has granted the rights to the chronic pain specialist BioDelivery Sciences (Nasdaq: BDSI), effective immediately, in return for an upfront cash payment of $20 million, an additional $10 million in six months, as well as quarterly royalty payments.

Symproic is an oral tablet which functions as a peripherally acting mu-opioid receptor antagonist medication. It is approved in the USA to be marketed for certain people with opioid-induced constipation (OIC).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK